Search
istradefylline (Nourianz)
Indication:
- add-on treatment to levodopa/carbidopa in adult patients with Parkinson's disease experiencing 'off' episodes
Adverse effects:
- dyskinesia, dizziness, constipation, nausea, hallucinations, insomnia
Mechanism of action:
- adenosine A2A receptor antagonist
General
adenosine A2A receptor antagonist
neurologic agent
Database Correlations
PUBCHEM cid=5311037
References
- FDA News Release. Aug 27, 2019
FDA approves new add-on drug to treat off episodes in adults
with Parkinson's disease.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-disease